Valuation: BioTime, Inc.

Market Cap 246M 219M 203M 184M 346M 23.3B 351M 2.43B 957M 12.19B 923M 904M 38.9B P/E 2026 *
-16.2x
P/E 2027 * -7.58x
Enterprise Value 246M 219M 203M 184M 346M 23.3B 351M 2.43B 957M 12.19B 923M 904M 38.9B EV / Sales 2026 *
16.2x
EV / Sales 2027 * 14.6x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 2018-09-16
Director of Finance/CFO 50 2022-11-13
Chief Tech/Sci/R&D Officer - 2024-03-31
Director TitleAgeSince
Director/Board Member 60 2009-06-30
Director/Board Member 68 2014-04-10
Chairman 60 2024-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+7.37%-11.55% - - 241M
+0.79%-6.16%+49.32%+74.50% 65.83B
+1.92%+10.35%+13.02%+87.74% 51.87B
+6.91%+8.57%+6.88%+72.12% 51.2B
+0.74%+2.75%+26.31%+45.29% 43.76B
+3.87%+10.15%+20.69%+132.73% 42.09B
+7.91%+4.30%+263.91%+602.72% 39.04B
-0.40%+9.85%+17.04%+59.17% 34B
+1.00%+1.73%+40.48%+9.64% 25.2B
+2.36%+5.34%+30.98%+26.07% 22.8B
Average +3.26%+1.67%+52.07%+123.33% 41.76B
Weighted average by Cap. +2.87%+2.01%+50.31%+125.32%

Financials

2026 *2027 *
Net sales 15.19M 13.52M 12.53M 11.36M 21.34M 1.44B 21.7M 150M 59.08M 753M 56.99M 55.81M 2.4B 16.83M 14.98M 13.89M 12.58M 23.65M 1.59B 24.05M 167M 65.46M 835M 63.15M 61.84M 2.66B
Net income -22.64M -20.15M -18.68M -16.92M -31.81M -2.14B -32.34M -224M -88.04M -1.12B -84.92M -83.16M -3.58B -34.44M -30.65M -28.41M -25.74M -48.38M -3.26B -49.19M -341M -134M -1.71B -129M -127M -5.45B
Net Debt - -
Logo BioTime, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - BioTime, Inc.